艾滋病毒研究忽略了女性

尽管病毒几乎平等地影响男性和女性，但在HIV治疗的临床试验中，妇女的人为不足。

Asystematic review发表在获得的免疫缺乏综合症杂志发现妇女约占抗逆转录病毒治疗的临床研究，其中约有19％的患者，参与疫苗试验的患者中有38％和HIV治疗研究的患者中有11％。该分析基于PubMed数据库中可用的544项已发表的研究，总计144,033名患者。

Ifgender临床样本中的比例偏差，研究的结果不能推广到其他人群中。

“越来越多的证据表明男人和女人之间的差异会影响疾病profile [and] prevalence, as well as drug uptake [and] metabolism,” she says. “If women are not included in adequate numbers and if potential differences are not looked for, there is a risk of treatment and prevention efforts not being optimised and even potentially causing harm in women.”

该分析的另一个发现是，公共资助的试验的女性少于私人资源资助的妇女。库诺说：“研究中有性别平等的任务，但必须执行。”

But she sounds a positive note, saying that the number of women involved in HIV research has been growing over time. For example, the proportion of female participants in antiretroviral therapy trials has increased in the past 20 years, but is still far from parity.

“If women are not included, there is a risk of treatment and prevention efforts not being optimised and even potentially causing harm in women.”

Mirjam Curno, Swiss Federal Institute of Technology

维罗妮卡米勒,美国执行主任rtnership the Forum for Collaborative HIV Research, tellsscidev.netthat including more women in HIV trials will bring not only clinical advantages, but also social ones.

米勒说：“参与研究带来了许多其他经常追踪的好处。”例如，参与临床研究的妇女可能会感到“对研究过程的所有权”，寻求“额外的诊所访问，而且通常更好healthcare”，并获得“有助于更大的利益”的感觉。

米勒说，患有低比例的女性参与者的研究可能不道德，因为我们不能证明她们有系统地排除妇女。但是她补充说：“我们需要问自己：它们是否反映了参与研究的当事方的价值观，原则和责任？”

这是Scidev.net的拉丁美洲和加勒比海台制作的文章的版本。